XML 24 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues $ 7,489,479 $ 3,172,279
Cost of revenues 6,228,256 3,368,612
Research and development 5,876,178 6,803,632
Selling, general, and administrative 6,458,331 11,087,899
Total operating costs and expenses 18,562,765 21,260,143
Operating loss (11,073,286) (18,087,864)
Other income (expense):    
Other income (expense), net 5,685 (546,027)
Interest expense (926,817) (550,964)
Nonoperating Income (Expense), Total (921,132) (1,096,991)
Loss before provision for income taxes and noncontrolling interests (11,994,418) (19,184,855)
Provision for income taxes 53,378 46,633
Net loss (12,047,796) (19,231,488)
Less - loss attributable to noncontrolling interests (66,879) (44,592)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders $ (11,980,917) $ (19,186,896)
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders $ (0.21) $ (0.51)
Weighted average common shares outstanding 57,380,438 37,594,894
Available for sale securities - net unrealized loss $ (486) $ (1,329)
Total other comprehensive loss (486) (1,329)
Comprehensive loss (12,048,282) (19,232,817)
Comprehensive loss attributable to noncontrolling interests (66,879) (44,592)
Comprehensive loss attributable to Caladrius Biosciences, Inc. common stockholders $ (11,981,403) $ (19,188,225)